



Sabine Yerly

Kontakt

Sabine Yerly

Publikationen (70)

Balakrishna S, Loosli T, Zaheri M, Frischknecht P, Huber M, Kusejko K, Yerly S, Leuzinger K, Perreau M, Ramette A, Wymant C, Fraser C, Kellam P, Gall A, Hirsch H, Stoeckle M, Rauch A, Cavassini M, Bernasconi E, Notter J, Calmy A, Günthard H, Metzner K, Kouyos R. Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1. *J Antimicrob Chemother* 2023; 78:656–664.

Labarile M, Loosli T, Zeeb M, Kusejko K, Huber M, Hirsch H, Perreau M, Ramette A, Yerly S, Cavassini M, Battegay M, Rauch A, Calmy A, Notter J, Bernasconi E, Fux C, Günthard H, Pasin C, Kouyos R. Quantifying and predicting ongoing Human Immunodeficiency Virus Type 1 (HIV-1) transmission dynamics in Switzerland using a distance-based clustering approach. *J Infect Dis* 2022

Chaudron S, Leemann C, Kusejko K, Nguyen H, Tschumi N, Marzel A, Huber M, Böni J, Perreau M, Klimkait T, Yerly S, Ramette A, Hirsch H, Rauch A, Calmy A, Vernazza P, Bernasconi E, Cavassini M, Metzner K, Kouyos R, Günthard H, Swiss HIV Cohort Study. A Systematic Molecular Epidemiology Screen Reveals Numerous Human Immunodeficiency Virus (HIV) Type 1 Superinfections in the Swiss HIV Cohort Study. *J Infect Dis* 2022; 226:1256–1266.

Nadeau S, Thorball C, Kouyos R, Günthard H, Böni J, Yerly S, Perreau M, Klimkait T, Rauch A, Hirsch H, Cavassini M, Vernazza P, Bernasconi E, Fellay J, Mitov V, Stadler T. A Phylogeny-aware GWAS Framework to Correct for Heritable Pathogen Effects on Infectious Disease Traits. *Mol Biol Evol* 2022; 39

Kusejko K, Tschumi N, Chaudron S, Nguyen H, Battegay M, Bernasconi E, Böni J, Huber M, Calmy A, Cavassini M, Egle A, Grabmeier-Pfistershammer K, Haas B, Hirsch H, Klimkait T, Öllinger A, Perreau M, Ramette A, Flury B, Sarcletti M, Scherrer A, Schmid P, Yerly S, Zangerle R, Günthard H, Kouyos R. Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics. *J Acquir Immune Defic Syndr* 2022; 90:e4–e12.

Nguyen H, Hampel B, Nuñez D, Battegay M, Hachfeld A, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Fellay J, Rudolph H, Huber M, Leuzinger K, Perreau M, Scherrer A, Ramette A, Yerly S, Günthard H, Kouyos R, Kusejko K. Correction to: Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. *Clin Infect Dis* 2022; 74:2266.

Scherrer A, Wandeler G, Fellay J, Bucher H, Yerly S, Suter F, Hirsch H, Huber M, Dollenmaier G, Perreau M, Martinetti G, Rauch A, Günthard H, Marzolini C, Tarr P, Traytel A, Braun D, Calmy A, Battegay M, Cavassini M, Furrer H, Schmid P, Bernasconi E, Stoeckle M, Kahlert C, Trkola A, Kouyos R, Swiss HIV Cohort Study (SHCS). Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). *Int J Epidemiol* 2021

Nguyen H, Leuzinger K, Perreau M, Scherrer A, Ramette A, Yerly S, Günthard H, Kouyos R, Kusejko K, Huber M, Rudolph H, Fellay J, Hampel B, Nuñez D, Battegay M, Hachfeld A, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Swiss HIV Cohort Study. Identifying and Characterizing Trans women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. *Clin Infect Dis* 2021

Duran Ramirez J, Kouyos R, Günthard H, Bernasconi E, Vernazza P, Furrer H, Stöckle M, Cavassini M, Yerly S, Ramette A, Perreau M, Hirsch H, Huber M, Chaudron S, Kusejko K, Nguyen H, Ballouz T, Swiss HIV Cohort Study. Increasing Frequency and Transmission of HIV-1 Non-B Subtypes among Men Who Have Sex with Men in the Swiss HIV Cohort Study. *J Infect Dis* 2021

Nguyen H, Kouyos R, Günthard H, Bernasconi E, Kahlert C, Cavassini M, Battegay M, Thurnheer M, Kusejko K, Hirsch H, Perreau M, Yerly S, Böni J, Fellay J, Thorball C, Swiss HIV Cohort Study. Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link. *Elife* 2021; 10

Thorball C, Klimkait T, Yerly S, Battegay M, Rauch A, Schmid P, Bernasconi E, Cavassini M, Kouyos R, Günthard H, Metzner K, Fellay J, Perreau M, Böni J, Wieser M, Borghesi A, Bachmann N, Von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, Bogoeska J, Roth V, Kok Y, Parbhoo S, Swiss HIV Cohort Study. Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. *J Acquir Immune Defic Syndr* 2020; 85:517-524.

Sculier D, Calmy A, Egger M, Limacher A, Schmid P, Günthard H, Decosterd L, Metzner K, Buzzi M, Cavassini M, Veraguth K, Braun D, Bernasconi E, Stoeckle M, Marinosci A, Yerly S, Wandeler G, and the Swiss HIV Cohort Study (SHCS). Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial. *PLoS Med* 2020; 17:e1003421.

Wan C, Yerly S, Battegay M, Walti L, Calmy A, Vernazza P, Bernasconi E, Cavassini M, Metzner K, Günthard H, Kouyos R, Klimkait T, Perreau M, Böni J, Bachmann N, Mitov V, Blanquart F, Céspedes S, Turk T, Neumann K, Beerenwinkel N, Bogoeska J, Fellay J, Roth V, Swiss HIV Cohort Study. Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. *Nat Commun* 2020; 11:5542.

Carlisle L, Günthard H, Bernasconi E, Vernazza P, Stoeckle M, Cavassini M, Nguyen A, Yerly S, Rauch A, Salazar-Vizcaya L, Fehr J, Braun D, Huber M, Böni J, Shah C, Mbunkah H, Metzner K, Turk T, Kouyos R. HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. *Viruses* 2020; 12

Pyngottu A, Günthard H, Bernasconi E, Vernazza P, Furrer H, Stöckle M, Cavassini M, Calmy A, Yerly S, Perreau M, Hirsch H, Huber M, Kouyos R, Scherrer A, Swiss HIV Cohort Study. Predictors of virological failure and time to viral suppression of first line integrase inhibitor based antiretroviral treatment. *Clin Infect Dis* 2020

Thorball C, Klimkait T, Yerly S, Battegay M, Rauch A, Schmid P, Bernasconi E, Cavassini M, Kouyos R, Günthard H, Metzner K, Fellay J, Perreau M, Böni J, Wieser M, Borghesi A, Bachmann N, Von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, Bogoeska J, Roth V, Kok Y, Parbhoo S, Swiss HIV Cohort Study. Host genomics of the HIV-1 reservoir size and its decay rate during suppressive antiretroviral treatment. *J Acquir Immune Defic Syndr* 2020

Bachmann N, Kouyos R, Günthard H, Cavassini M, Bernasconi E, Vernazza P, Ramette A, Rauch A, Battegay M, Yerly S, Klimkait T, Perreau M, Böni J, Turk T, Kadelka C, Chaudron S, Nguyen H, Kusejko K, Swiss HIV Cohort Study. Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of HIV Transmission in MSM. *Clin Infect Dis* 2020

Abela I, Günthard H, Bernasconi E, Cavassini M, Schmid P, Calmy A, Furrer H, Hirsch H, Perreau M, Klimkait T, Yerly S, Böni J, Scherrer A, Swiss HIV Cohort Study. Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. *Clin Infect Dis* 2020; 70:297-303.

Oleary F, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Boeni J, Bernasconi E, Günthard H, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagliola D, Schmid P, Calmy A. Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. *Open Forum Infect Dis* 2019; 6:ofz500.

Oleary F, D'arminio Monforte A, Zazzi M, Rossetti B, Neau D, Bellecave P, Rijnders B, Reiss P, Wit F, Kouyos R, Boeni J, Bernasconi E, Günthard H, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, Cavassini M, Scherrer A, Costagliola D, Schmid P, Calmy A. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. *Open Forum Infect Dis* 2019; 6:ofz330.

Compagno F, Hirsch H, Rudin C, Battegay M, Böni J, Yerly S, Paioni P, Martinez de Tejada B, Aebi-Popp K, Hösli I, Kahlert C, Naegele K, Swiss HIV Cohort Study. The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study. *Swiss Med Wkly* 2019; 149:w20059.

Carlisle L, Braun D, Rauch A, Calmy A, Cavassini M, Battegay M, Vernazza P, Bernasconi E, Günthard H, Kouyos R, Perreau M, Klimkait T, Yerly S, Turk T, Kusejko K, Metzner K, Leemann C, Schenkel C, Bachmann N, Posada S, Beerenwinkel N, Böni J, Swiss HIV Cohort Study. Viral diversity from next-generation sequencing of HIV-1 samples provides precise estimates of infection recency and time since infection. *J Infect Dis* 2019

Kusejko K, Kouyos R, Günthard H, Rauch A, Perreau M, Klimkait T, Yerly S, Böni J, Hoffmann M, Cavassini M, Calmy A, Bernasconi E, Battegay M, Marzel A, Kadelka C, Swiss HIV Cohort Study. Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. *Virus Evol* 2018; 4:vey024.

Kouyos R, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner K, Günthard H, Trkola A, Chave J, Kuster H, Leemann C, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun D, Scherrer A, Weber J, Uhr T, Baumann N, Swiss HIV Cohort Study. Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. *Nature* 2018; 561:406–410.

Kadelka C, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Kouyos R, Günthard H, Trkola A, Cavassini M, Misselwitz B, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun D, Huber M, Scherrer A, Weber J, Uhr T, Kuster H, Swiss HIV Cohort Study. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. *J Exp Med* 2018; 215:1589–1608.

Marzel A, Kouyos R, Günthard H, Perreau M, Klimkait T, Yerly S, Böni J, Hoffmann M, Cavassini M, Calmy A, Bernasconi E, Roth J, Rauch A, Bruggmann P, Weber R, Kusejko K, Swiss HIV Cohort Study. The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. *Open Forum Infect Dis* 2018; 5:ofy078.

Bertels F, Cavassini M, Calmy A, Bernasconi E, Schmid P, Scherrer A, Müller V, Bonhoeffer S, Kouyos R, Regoes R, Rauch A, Battegay M, Marzel A, Leventhal G, Mitov V, Fellay J, Günthard H, Böni J, Yerly S, Klimkait T, Aubert V, Swiss HIV Cohort Study. Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. *Mol Biol Evol* 2018; 35:27–37.

Yerly S, Marzolini C, Martinez de Tejada B, Martinetti G, Ledergerber B, Kovari H, Kouyos R, Klimkait T, Keiser O, Kaiser L, Kahlert C, Hösli I, Hoffmann M, Hirsch H, Hasse B, Metzner K, Müller N, Weber R, Wandeler G, Vernazza P, Trkola A, Tarr P, Stöckle M, Speck R, Schmid P, Scherrer A, Rudin C, Rauch A, Paioni P, Pantaleo G, Nicca D, Haerry D, Günthard H, Fux C, Kouyos R, Günthard H, Hoffmann M, Furrer H, Cavassini M, Calmy A, Bernasconi E, Battegay M, Klimkait T, Aubert V, Yerly S, Böni J, Kadelka C, Bachmann N, Swiss HIV Cohort Study, Aubert V, Furrer H, Fellay J, Fehr J, Elzi L, Egger M, Dollenmaier G, Ciuffi A, Cavassini M, Calmy A, Bucher H, Braun D, Böni J, Bernasconi E, Battegay M, Turk T. Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. *Elife* 2017; 6

Rusert P, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Fellay J, Regoes R, Günthard H, Trkola A, Cavassini M, Kuster H, Kouyos R, Kadelka C, Ebner H, Schanz M, Huber M, Braun D, Hozé N, Scherrer A, Magnus C, Weber J, Uhr T, Cippa V, Thorball C. Determinants of HIV-1 broadly neutralizing antibody induction. *Nat Med* 2016

Shilaih M, Kouyos R, Günthard H, Furrer H, Bernasconi E, Vernazza P, Klimkait T, Cavassini M, Aubert V, Hirsch H, Yerly S, Böni J, Schüpbach J, Scherrer A, Yang W, Marzel A, Swiss HIV Cohort Study. Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. *Sci Rep* 2016; 6:27580.

Scherrer A, Günthard H, Bernasconi E, Schmid P, Calmy A, Hauser C, Battegay M, Cavassini M, Aubert V, Klimkait T, Yerly S, Böni J, Kouyos R, Yang W. Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. *J Infect Dis* 2016; 214:399–402.

Scherrer A, Günthard H, Bernasconi E, Vernazza P, Calmy A, Furrer H, Battegay M, Cavassini M, Aubert V, Klimkait T, Yerly S, Böni J, Kouyos R, Yang W, von Wyl V. Emergence of acquired HIV-1 drug resistance has almost been stopped in Switzerland – a 15 year prospective cohort analysis. Clin Infect Dis 2016

Aouri M, Rotger M, Telenti A, Buclin T, Günthard H, Vernazza P, Henry H, Yerly S, Anagnostopoulos A, Cavassini M, TERNON B, Barcelo C, Decosterd L. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine and Cerebro-Spinal Fluid. Drug Metab Dispos 2015

Marzel A, Kouyos R, Günthard H, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Furrer H, Calmy A, Braun D, Aubert V, Klimkait T, Yerly S, Böni J, Yang W, Shilaih M, Swiss HIV Cohort Study. HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. Clin Infect Dis 2015

Yang W, Swiss HIV Cohort Study (SHCS), Günthard H, Ledergerber B, Held L, Vernazza P, Bernasconi E, Cavassini M, Battegay M, Hirzel C, Aubert V, Klimkait T, Yerly S, Shah C, Böni J, Scherrer A, Kouyos R, Swiss HIV Cohort Study SHCS. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. J Antimicrob Chemother 2015

Yang W, Günthard H, Ledergerber B, Held L, Vernazza P, Bernasconi E, Cavassini M, Battegay M, Furrer H, Aubert V, Klimkait T, Yerly S, Shah C, Böni J, Scherrer A, Kouyos R, Swiss HIV Cohort Study. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. J Infect Dis 2015

Vetter B, Böni J, Shah C, Yerly S, Suter-Riniker F, Schottstedt V, Schmid P, Regenass S, Klimkait T, Dollenmaier G, Ciardo D, Brandenberger M, Aubert V, Niederhauser C, Fransen K, Orłowski V, Schüpbach J. Generation of a Recombinant Gag Virus-Like-Particle Panel for the Evaluation of p24 Antigen Detection by Diagnostic HIV Tests. PLoS one 2014; 9:e111552.

Metzner K, Günthard H, Weber R, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Hirsch H, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, von Wyl V, Scherrer A, the Swiss HIV Cohort Study. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naïve patients. AIDS 2014; 28:2231-2239.

Kouyos R, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Calmy A, Kovari H, Shah C, Aubert V, Klimkait T, Yerly S, Böni J, Yang W, Braun D, Rauch A, Günthard H. Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. J Infect Dis 2014; 210:1555-61.

Kouyos R, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Calmy A, Kovari H, Klimkait T, Aubert V, Shah C, Yerly S, Böni J, Rauch A, Swiss HIV Cohort Study (SHCS). Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. Int J Epidemiol 2014; 43:887-96.

Bartha I, Yerly S, O'Brien S, Listgarten J, Pfeifer N, Lippert C, Fusi N, Kutalik Z, Allen T, Müller V, Harrigan P, Heckerman D, Telenti A, Klimkait T, Vernazza P, Bernasconi E, Carlson J, Brumme C, McLaren P, Brumme Z, John M, Haas D, Martinez-Picado J, Dalmau J, López-Galíndez C, Casado C, Rauch A, Günthard H, Fellay J. A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. Elife 2013; 2:e01123.

Drescher S, Kouyos R, Günthard H, Ledergerber B, Vernazza P, Bernasconi E, Cavassini M, Ambrosioni J, Battegay M, Furrer H, Taffé P, Klimkait T, Aubert V, Shah C, Yerly S, Böni J, Yang W, von Wyl V, Swiss HIV Cohort Study. Treatment-naïve individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis 2013; 58:285-94.

von Wyl V, Glass T, Bucher H, Günthard H, Aubert V, Böni J, Bernasconi E, Calmy A, Cavassini M, Furrer H, Nicca D, Yerly S, Klimkait T, Swiss HIV Cohort Study. Adherence as a predictor of the development of class-specific resistance mutations: the Swiss HIV Cohort Study. *PloS one* 2013; 8:e77691.

Beerenwinkel N, Günthard H, Celleraï C, Klimkait T, Böni J, Yerly S, Bernasconi E, Vernazza P, Cavassini M, Hirschel B, Battegay M, Furrer H, von Wyl V, Knupfer P, Schuhmacher H, Montazeri H, Swiss HIV Cohort Study. The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. *PLoS Comput Biol* 2013; 9:e1003203.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, the Swiss HIV Cohort Study (SHCS). Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. *PloS one* 2013; 8

Metzner K, Aubert V, Furrer H, Battegay M, Vernazza P, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard H, Klimkait T, Yerly S, Böni J, Scherrer A, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Swiss HIV Cohort Study. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. *J Infect Dis* 2013; 208:1102-12.

Du Pasquier R, Vernazza P, Cavassini M, Günthard H, Cusini A, Gutmann C, Fux C, Yerly S, Kalubi M, Jilek S, Swiss HIV Cohort Study. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. *AIDS* 2013; 27:203-10.

Cusini A, Günthard H, Opravil M, Gutmann C, Zenger F, Klimkait T, Cavassini M, Gaudenz R, Hirschel B, Widmer N, Rohrbach J, Fux C, Ledergerber B, Decosterd L, Yerly S, Vernazza P, Swiss HIV Cohort Study. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. *J Acquir Immune Defic Syndr* 2013; 62:28-35.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. *PloS one* 2012; 7:e50307.

Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Celleraï C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. *PloS one* 2012; 7:e37983.

von Wyl V, Günthard H, Ledergerber B, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Celleraï C, Shah C, Böni J, Yerly S, Swiss HIV Cohort Study. Incidence of HIV-1 drug resistance among antiretroviral treatment-naïve individuals starting modern therapy combinations. *Clin Infect Dis* 2011; 54:131-40.

Scherrer A, Günthard H, Held L, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Hirschel B, Rauch A, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. *Clin Infect Dis* 2011; 53:1143-52.

von Wyl V, Günthard H, Bonhoeffer S, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Staehelin C, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Böni J, Yerly S, Kouyos R, Swiss HIV Cohort Study. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. *J Infect Dis* 2011; 204:1095-103.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Hirschel B, Garzoni C, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Swiss HIV Cohort Study (SHCS). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. *J Acquir Immune Defic Syndr* 2011; 57:24–31.

Fehr J, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard H, Battegay M, Bucher H, Klimkait T, Fux C, Cavassini M, Glass T, Louvel S, Hamy F, Hirsch H, von Wyl V, Böni J, Yerly S, Bürgisser P, Hiv Cohort Study A. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals – the Swiss HIV Cohort Study. *J Transl Med* 2011; 9:14.

Kouyos R, Cavassini M, Rauch A, Battegay M, Vernazza P, Bernasconi E, Ledergerber B, Bonhoeffer S, Günthard H, Hirschel B, Weber R, Klimkait T, von Wyl V, Yerly S, Böni J, Rieder P, Joos B, Taffé P, Shah C, Bürgisser P, Swiss HIV Cohort Study. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. *Clin Infect Dis* 2011; 52:532–9.

Alizon S, Bonhoeffer S, Günthard H, Telenti A, Bürgisser P, Battegay M, Bernasconi E, Vernazza P, Rauch A, Furrer H, Klimkait T, Shah C, Böni J, Hirschel B, Yerly S, Kouyos R, Stadler T, von Wyl V, Swiss HIV Cohort Study. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. *PLoS Pathog* 2010; 6

Gutmann C, Vernazza P, Yerly S, Cavassini M, Decosterd L, Hirschel B, Fux C, Günthard H, Cusini A, Swiss HIV Cohort Study (SHCS). Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4–nadir. *AIDS* 2010; 24:2347–54.

Kouyos R, Bonhoeffer S, Ledergerber B, Rickenbach M, Bernasconi E, Vernazza P, Battegay M, Furrer H, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Taffé P, Böni J, Yerly S, von Wyl V, Günthard H. Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland. *J Infect Dis* 2010; 201:1488–97.

Witteck A, Yerly S, Vernazza P. Unusually high HIV infectiousness in an HIV–, HCV– and HSV–2–coinfected heterosexual man. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2009; 139:207–9.

von Wyl V, Günthard H, Ledergerber B, Bonhoeffer S, Francioli P, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Yerly S, Swiss HIV Cohort Study. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2009; 48:979–87.

von Wyl V, Günthard H, Ledergerber B, Rickenbach M, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, Swiss HIV Cohort Study. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2008; 46:1299–309.

Schüpbach J, Daneel S, Staub R, Güntert B, Martinetti G, Andreutti C, Steffen I, Schultze D, Dubs R, Gorgievski M, Matter L, Bürgisser P, Yerly S, Niederhauser C, Tomasik Z, Gebhardt M, Vernazza P. Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. *PLoS medicine* 2007; 4:e343.

Wolbers M, Bucher H, Günthard H, Yerly S, Battegay M, Bernasconi E, Vernazza P, Cavassini M, Furrer H, Hirschel B, von Wyl V, Opravil M, Swiss HIV Cohort Study. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. *AIDS (London, England)* 2007; 21:2201–7.

von Wyl V, Günthard H, Ledergerber B, Perrin L, Rickenbach M, Bernasconi E, Vernazza P, Hirschel B, Telenti A, Furrer H, Battegay M, Klimkait T, Bürgisser P, Böni J, Yerly S, for the Swiss HIV Cohort Study. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. *Archives of internal medicine* 2007; 167:1782-90.

Ananworanich J, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B, Staccato Study Group, Bernasconi E, Vernazza P, Nüesch R, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genné D, Swiss HIV Cohort Study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. *Lancet* 2006; 368:459-65.

Schüpbach J, Hirschel B, Bernasconi E, Vernazza P, Furrer H, Battegay M, Perrin L, Yerly S, Tomasik Z, Böni J, Fischer M, Joos B, Günthard H, Swiss HIV Cohort Study. HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss. *Journal of acquired immune deficiency syndromes (1999)* 2005; 40:250-6.

Yerly S, Perrin L, Hirschel B, Perneger T, Bernard M, Gebhardt M, Rickenbach M, Bürgisser P, Chanzy B, Furrer H, Battegay M, Vernazza P, Chave J, Kaiser L, Flepp M, Telenti A, Jost S, Swiss HIV Cohort Study. Infrequent transmission of HIV-1 drug-resistant variants. *Antiviral therapy* 2004; 9:375-84.

Fagard C, Price D, Dawson S, Klimkait T, Perneger T, McLean A, Clotet B, Gatell J, Perrin L, Plana M, Phillips R, Hirschel B, Yerly S, Leduc D, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Swiss HIV Cohort Study. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. *Archives of internal medicine* 2003; 163:1220-6.

Opraval M, Perrin L, Weber R, Howe C, Günthard H, Ledergerber B, Battegay M, Bernasconi E, Vernazza P, Fischer M, Bisset L, Yerly S, Chave J, Furrer H, Lazzarin A, Hirschel B, Swiss HIV Cohort Study. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. *The Journal of infectious diseases* 2002; 185:1251-60.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch